A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

NCT07691762 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

690

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: SHR-8068 + Adebrelimab + Bevacizumab
DRUG: SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo
DRUG: SHR-8068 Placebo + Adebrelimab + Bevacizumab

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.